Bioloupe provides an oncology and hematology intelligence platform that lets users ask clinical and market questions in plain language and receive source-linked answers the same day. It combines curated data on drugs, trials, publications, and disease landscapes with built-in forecasting and target product profile workflows. The platform covers 13,000+ deduplicated drugs and 90,000+ US and China trials in one comparable dataset.
- Artificial Intelligence
- Data & Analytics
- Biotechnology
- Drug Discovery & Therapeutics
- Enterprise Software
- Healthcare Technology
- Software Only
Funding
Founders
Product
Problem
Oncology and hematology teams trying to assess a drug opportunity, review clinical evidence, or build a market forecast typically rely on multiple disconnected databases, manual data collection, and spreadsheet handoffs. This process takes two to three weeks per analysis, requires multiple software licenses, and produces results that are difficult to trace back to their original sources, slowing strategic decision-making.
Solution
Bioloupe is an oncology and hematology intelligence platform that consolidates curated clinical and commercial data into a single evidence base, enabling users to ask questions in plain language and receive structured, source-linked answers the same day. The platform supports end-to-end workflows from landscape mapping and clinical benchmarking to forecasting and management deck creation, with Monte Carlo simulations for market modeling. Every output—from treatment arm results to forecast assumptions—links back to the trial, label, publication, or input behind it, ensuring full traceability. Users can also build and refine target product profiles directly within the platform, eliminating the need for separate data and forecasting licenses.
Target Audience
Primary users are oncology and hematology strategy teams, clinical development groups, and commercial market access functions at pharmaceutical and biotech companies who need rapid, defensible landscape assessments, clinical evidence comparisons, and market forecasts.
Features
- Plain-language query interface that returns standard of care by line, development landscape, relevant trials, and per-arm results in a structured dataset
- Pre-built disease models with adjustable epidemiology, treatment line, and patient flow assumptions, running Monte Carlo simulations to identify key input sensitivities
- Clinical benchmarking tools that compare patient populations, biomarkers, arms, comparators, endpoints, efficacy, and safety with forest plot generation
- Source-linked management deck drafting, where every number can be traced to its underlying trial, label, publication, or assumption
- Curated dataset covering 13,000+ deduplicated drugs, 90,000+ US and China trials, 225,000+ publications, 1.2M+ reported results, 550+ disease standards of care, and 7,800+ organizations with pipelines, deals, and filings
- Cross-regulatory coverage with approvals and labels from the US, Europe, Japan, and China, plus investor presentations, SEC filings, financials, and product sales data
- Target product profile (TPP) building functionality integrated into the same platform as research and forecasting workflows